Neurology Minute

Dr. Vikram Karnak discusses the novel hereditary ataxia SCA27b, its genetic basis, symptoms, and potential treatments, emphasizing the need for testing in unexplained adult-onset ataxia.

In part two of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss the link between HSV and NMDAR encephalitis and how that impacts longitudinal recovery. Show reference: https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000210109

In part two of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss the link between HSV and NMDAR encephalitis and how that impacts longitudinal recovery. Show reference: https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000210109

In this enlightening discussion, experts delve into the long-term recovery of patients with anti-NMDAR encephalitis. They highlight the serious cognitive and functional deficits that arise from this condition. Tailored rehabilitation strategies are emphasized to address challenges in executive functioning and memory. The implications for improving patients' overall quality of life take center stage, offering hope and insight for ongoing recovery efforts.

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss abandoning the term lupus myelitis and emphasize the importance of accurately naming and identifying each autoimmune condition. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss key features of inflammatory myelopathy in rheumatologic disease, helping to better characterize the underlying causes of lupus myelitis. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329

Discover the intriguing potential of GLP-1 receptor agonists in combating neurologic disorders. The discussion highlights a fascinating case study showcasing improvements in migraine symptoms. Delve into the emerging interest around these weight loss medications and their possible benefits for brain health. It's a captivating look at how a medication designed for obesity might hold the key to better neurological outcomes.

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548

Dr. Gregg Day and Dr. Kathryn T. Hall discuss the complexities of the placebo effect, its variability among patients, and the genetic factors that influence responses to placebo treatments.

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548